Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Cypherpunk Technologies Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Cypherpunk Technologies Inc. has 7 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Cypherpunk Technologies Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Cypherpunk Technologies Inc.. Customers appear here when Cypherpunk Technologies Inc. names them, or when a company names Cypherpunk Technologies Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We participate, through our subsidiary in Australia, in the Australian government's R&D Incentive program, such that a percentage of our eligible research and development expenses are reimbursed by the Australian government as a refundable tax offset and such incentives are reflected as other income.”
FILING10-K0001104659-26-028566cik 0001509745
“We hold digital assets in the form of Zcash with Gemini, a third-party custodian ("Gemini").”
FILING10-K0001104659-26-028566cik 0001509745
“We exclusively license from Eli Lilly and Company ("Lilly"), rights under 26 issued patents and 1 pending patent application, all of which belong to the same patent family.”
FILING10-K0001104659-26-028566cik 0001509745
“Our sirexatamab bulk drug substance ("DS"), is produced at our CMO, ThermoFisher Scientific, which is required to comply with the FDA's Current Good Manufacturing Practice ("cGMP") regulations.”
FILING10-K0001104659-26-028566cik 0001509745
“On August 10, 2020, we entered into a collaboration agreement with Adimab, LLC (the "Adimab Agreement"), pursuant to which Adimab will conduct research programs to develop monoclonal antibodies to certain targets identified by us and provide us with an option to acquire exclusive rights to such antibodies.”
FILING10-K0001104659-26-028566cik 0001509745
“In patients with high circulating DKK1 plasma levels (upper quartile as measured by the SomaLogic SomaScan platform, n=44), the sirexatamab experimental arm has improved ORR, by both investigator-assessment ("IA") and blinded independent central review ("BICR"), PFS, and OS compared to the control arm:”
FILING10-K0001104659-26-028566cik 0001509745
“Published data, including from The Cancer Genome Atlas ("TCGA") and real world evidence from our collaboration with Tempus, indicate that DKK1 levels are significantly higher or have an important high DKK1 population in many cancers, including esophagogastric cancer, non-small cell lung cancer, endometrial cancer, CRC, and pancreatic cancer.”
FILING10-K0001104659-26-028566cik 0001509745
Watchlist prices, news filtered to it, and its next report on your desk.
CYPH (Cypherpunk Technologies Inc.) has 7 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.